Tizanidine

Tizanidine is a short-acting, centrally acting skeletal muscle relaxant that belongs to the imidazoline class of alpha-2 adrenergic receptor agonists ^[1]. Chemically it is a derivative of benzothiadiazole and is closely related to the antihypertensive drug clonidine, though it lowers blood pressure far more weakly, on the order of one-tenth to one-fifteenth as much. Its molecular formula is C9H8ClN5S with a molar mass of about 254 g/mol.

The drug is used chiefly to manage spasticity, the involuntary muscle tightness and spasms that accompany multiple sclerosis, stroke, spinal cord injury, and cerebral palsy ^[1]. Clinical trials have found its effectiveness comparable to the other oral antispastic agents baclofen and diazepam, with overall tolerability data often favoring tizanidine ^[1]. It has also been used off-label for purposes such as tension headache, migraine, and difficulty sleeping. The United States Food and Drug Administration approved tizanidine in 1996, and it is now widely available as a generic medication that remains prescription-only, ranking among the more commonly prescribed drugs in the United States. It is taken by mouth as tablets or capsules, marketed under names including Zanaflex and Sirdalud.

Tizanidine is absorbed rapidly and has a short elimination half-life of roughly two to three hours, so its effect is relatively brief and doses are often timed to periods when relief is most needed ^[1]. It is metabolized almost entirely in the liver by the enzyme CYP1A2, which leaves it open to major drug interactions ^[2]. Combining it with potent CYP1A2 inhibitors is hazardous; the antidepressant fluvoxamine raised tizanidine exposure roughly thirty-three-fold in a controlled study, producing marked drops in blood pressure and heavy sedation, and such combinations, including fluoroquinolone antibiotics like ciprofloxacin, are contraindicated ^[2]. In overdose, tizanidine characteristically causes drowsiness, slow heart rate, and low blood pressure, which are generally managed with supportive care ^[3].

This is a prescription medicine. Common effects are drowsiness, dry mouth, weakness, dizziness, and low blood pressure. Worth watching: it can raise liver enzymes, so occasional blood tests make sense, and it can slow the heart. It is broken down by the liver enzyme CYP1A2, so it must not be combined with strong CYP1A2 inhibitors such as ciprofloxacin or fluvoxamine; those send its levels sharply higher and can trigger dangerous drops in blood pressure and heavy sedation. Use caution alongside other blood-pressure drugs and central nervous system depressants, and taper the dose rather than stopping suddenly, since an abrupt halt can cause rebound high blood pressure and a racing heart.

Tizanidine is cleared almost entirely by CYP1A2 and has low oral bioavailability because so much of it is destroyed on first pass. That combination makes it unusually vulnerable: anything inhibiting CYP1A2 removes the first-pass barrier, and exposure climbs steeply.

Fluvoxamine is the extreme case, raising tizanidine AUC roughly 33-fold. Ciprofloxacin raises AUC about 10-fold and peak concentration 7-fold; in healthy volunteers systolic pressure fell 35 mmHg on ciprofloxacin against 15 mmHg on placebo, with markedly more sedation. Both combinations are contraindicated. Adverse event reporting shows the same signal in practice, with hypotension, syncope, falls and fractures reported far more often when tizanidine and a CYP1A2 inhibitor appear together.

Weaker inhibitors matter in proportion: oral contraceptives roughly halve tizanidine clearance, and zileuton, zafirlukast, cimetidine, amiodarone, mexiletine, propafenone, verapamil and ticlopidine all raise exposure.

Separately, tizanidine is an alpha-2 agonist, so it adds to the hypotension of antihypertensives, including clonidine, and to the sedation of alcohol, benzodiazepines, opioids and baclofen.

Checking a whole stack? Run it through interactions + stacks.

Tizanidine is a centrally acting muscle relaxant developed by the Swiss pharmaceutical company Sandoz, emerging from research on imidazoline compounds structurally related to the antihypertensive clonidine. Chemists found that this alpha-2 adrenergic agonist strongly reduced muscle tone while exerting far weaker effects on blood pressure than clonidine, which directed its development toward the treatment of spasticity rather than hypertension.

It was introduced in Europe in the 1980s under brand names such as Sirdalud and received United States Food and Drug Administration approval in 1996, where it is marketed as Zanaflex. Clinical studies established its usefulness in reducing the painful, excessive muscle tone caused by conditions such as multiple sclerosis, stroke, and spinal cord injury. Tizanidine has since become a widely used option in the management of spasticity and is available as an inexpensive generic in tablet and capsule forms.

Tizanidine is a well-established and widely prescribed muscle relaxant, particularly valued for treating the spasticity of multiple sclerosis and spinal cord injury, where it appears in standard treatment algorithms as a core option. Clinicians appreciate that it calms overactive spinal reflexes without substantially reducing muscle strength, since it acts centrally on nerve signaling rather than directly on muscle fibers, and its relatively short duration of action allows dosing to be timed to periods when relief is most needed.

It is often chosen when a comparatively favorable side-effect balance is desired relative to alternatives. Candor is warranted about its cautions: drowsiness, dry mouth, low blood pressure, and occasional liver enzyme elevations are recognized, and because it is cleared by the liver enzyme CYP1A2, combining it with strong inhibitors of that enzyme can dangerously raise its levels. Used thoughtfully, tizanidine remains a trusted and effective tool for a difficult symptom.